BeOne Medicines (ONC) Revenue Growth (3y) (2018 - 2026)
Powered by 
Analysis
BeOne Medicines (ONC) Revenue Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 5.56% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 7.01% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 3.37% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 8.00% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 4.95% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 7.50% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 42.02% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 20.59% |
| 10 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 9.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.02% |
| Mar 31, 2026 | 50.07% |
| Dec 31, 2025 | 57.96% |
| Sep 30, 2025 | 53.88% |
| Jun 30, 2025 | 56.74% |
| Mar 31, 2025 | 53.88% |
| Dec 31, 2024 | 74.03% |
| Sep 30, 2024 | 69.29% |
| Jun 30, 2024 | 83.66% |
| Mar 31, 2024 | 7.45% |
| Dec 31, 2023 | 85.06% |
| Sep 30, 2023 | 104.71% |
| Jun 30, 2023 | 108.54% |
| Mar 31, 2023 | 104.89% |
| Dec 31, 2022 | 88.34% |
| Sep 30, 2022 | 97.73% |
| Jun 30, 2022 | 11.97% |
| Mar 31, 2022 | 57.94% |
| Dec 31, 2021 | 53.93% |
| Sep 30, 2021 | 56.17% |